425: Alumis and ACELYRIN Amend Merger Agreement, Increasing ACELYRIN Stockholder Ownership

Alumis and ACELYRIN have amended their merger agreement, increasing the ownership stake for ACELYRIN stockholders in the combined company to approximately 48% on a fully diluted basis.

Summary

• Alumis and ACELYRIN have amended their previously announced merger agreement.
• Under the amended terms, ACELYRIN stockholders will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock.
• This revision results in Alumis stockholders owning approximately 52% and ACELYRIN stockholders owning approximately 48% of the combined company on a fully diluted basis.
• The boards of both companies, acting on the recommendation of special committees, have unanimously approved the amended agreement.
• Both companies will hold a Special Meeting of Stockholders on May 13, 2025, to approve the transaction.
• The companies expect to close the transaction during the second quarter of 2025, subject to stockholder approval and customary closing conditions.
• The combined company expects to have a pro forma cash position of approximately $737 million as of December 31, 2024, providing runway into 2027.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the improved terms for ACELYRIN stockholders and the expected benefits of the merger, such as a stronger financial position and diversified pipeline. However, risks associated with the merger and integration temper the overall sentiment.

Positives

• ACELYRIN stockholders will receive increased ownership in the combined company.
• The merger is expected to create a leading clinical-stage immunology company with a diversified portfolio.
• The combined company is expected to have sufficient cash runway to advance its pipeline through multiple key data readouts and fund operations into 2027.
• The amended agreement was unanimously recommended and approved by the disinterested directors of each company's board.

Negatives

• The merger is subject to stockholder approval and customary closing conditions, which introduces uncertainty.
• The integration of the two companies post-merger may not occur as anticipated, potentially affecting growth prospects.
• The announcement and pendency of the merger could divert management's attention from ongoing business operations.

Risks

• The proposed merger may not be completed in a timely manner or at all.
• Required approvals, including stockholder approvals, may not be received.
• The merger could negatively impact the ability to attract and retain key personnel.
• The anticipated benefits and synergies of the merger may not be fully realized or may take longer to realize than expected.
• There are risks associated with integrating the operations and personnel of the two companies.
• The combined company faces risks related to developing, commercializing, and manufacturing product candidates.
• The value of Alumis securities to be issued in the merger is subject to market fluctuations.

Future Outlook

The combined company expects to advance its pipeline through multiple planned key data readouts across several clinical trials and to fund operating expenses and capital expenditure requirements into 2027.

Management Comments

• Martin Babler, President, Chief Executive Officer and Chairman of Alumis, stated that the revised terms enable enhanced value creation opportunities for stockholders and provide financial flexibility to advance the pipeline.
• Bruce Cozadd, Chair of the ACELYRIN Board of Directors, said that the amended agreement reflects dialogue with stockholders and builds upon the previously announced agreement.

Industry Context

The merger aims to create a leading clinical-stage immunology company, reflecting a trend in the biopharmaceutical industry towards consolidation to diversify pipelines and enhance financial resources.

Comparison to Industry Standards

• The merger between Alumis and ACELYRIN is similar to other mergers in the biopharmaceutical industry, such as the acquisition of Immunomedics by Gilead Sciences, which aimed to expand their oncology pipeline.
• The pro forma cash position of $737 million is comparable to other clinical-stage companies with late-stage assets, providing a runway for clinical development and potential commercialization.
• The exchange ratio of 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock is within the typical range for mergers of this type, reflecting the relative valuations of the two companies.

Stakeholder Impact

• ACELYRIN stockholders will benefit from increased ownership in the combined company.
• Alumis stockholders will benefit from the expanded pipeline and financial flexibility.
• Employees of both companies may experience changes related to the integration of the two organizations.
• Patients may benefit from the development of new therapies resulting from the combined company's research and development efforts.

Next Steps

• Alumis and ACELYRIN will file supplemental proxy materials with the SEC.
• The companies will hold their respective Special Meetings of Stockholders on May 13, 2025.
• The companies will work towards closing the transaction in the second quarter of 2025, subject to approvals and conditions.

Key Dates

Keywords

merger, ACELYRIN, Alumis, stockholders, agreement, immunology, clinical-stage, pipeline